Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)

Launched by CORCEPT THERAPEUTICS · Feb 13, 2025

Keywords

ClinConnect Summary

The MOMENTUM trial is studying how common a condition called endogenous hypercortisolism (eHC) is in people who have resistant hypertension (rHTN), which is high blood pressure that doesn’t respond to standard treatments. The study aims to enroll about 1,000 patients across 45 locations in the U.S. If you have high blood pressure despite taking three or more different medications, or if you're taking four or more to keep your blood pressure under control, you might be eligible to participate.

If you join the trial, you’ll first have a screening visit where your medical history will be reviewed, and a physical exam will be done. You’ll then take a small dose of a medication called dexamethasone the night before a blood test to check your cortisol levels. If the results show you have eHC, you’ll come in for another visit for additional blood tests and possibly a CT scan. This study does not involve any new medications or treatments; it’s focused on understanding the condition better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Each patient must meet all of the following criteria to be enrolled in the study:
• • Signed and dated Institutional Review Board (IRB)-approved informed consent form (ICF) prior to any study-specific screening procedures.
• • Male/female patients must be 18 years or older at the time of signing the informed consent.
• * Meet either of the following criteria:
• • Has rHTN, defined by the American Heart Association as BP above target (systolic ≥ 130 mmHg for purposes of this study) despite concurrent use of 3 or more antihypertensive medications from different classes at their maximally tolerated doses, and 1 of these agents is a diuretic.
• • Has rHTN, defined by the American Heart Association as BP at target (systolic \< 130 mmHg) or above target requiring concurrent use of 4 or more antihypertensive medications of different classes.
• Exclusion Criteria:
• * Patients who meet any of the following criteria will not be permitted entry to the study:
• • White coat hypertension, ie, elevated BP in the office only, as determined by the Investigator.
• • Non-adherence to BP medications, as determined by the Investigator.
• • Systemic glucocorticoid medications exposure (excluding inhalers or topical) within 3 months of screening. For temporary exposures to oral glucocorticoids the Medical Monitor may be consulted to determine eligibility.
• • Has an historical estimated glomerular filtration rate (eGFR) \< 30.
• • Has severe untreated sleep apnea as determined by the Investigator.
• • Has excessive alcohol consumption (eg, \> 14 units/week for male, \> 7 units/week for female) as determined by the Investigator.
• • Has severe acute psychiatric, medical, or surgical illness, as determined by the Investigator.
• • Is a woman who is pregnant or lactating. For women of childbearing potential, a urine pregnancy test must be negative before doing the DST. A woman of childbearing potential includes women \< 50 years old, women whose surgical sterilization was performed \< 6 months ago, and women who have had a menstrual period in the last 12 months.
• • Is a woman who is on oral contraceptive pills (OCPs). Women on OCPs may be screened but must be willing and able to stop OCPs for at least 6 weeks prior to screening assessments. OCPs can be resumed immediately after the blood draw for the DST.
• • Has history of congenital adrenal hyperplasia.
• * Has had the diagnosis of Cushing syndrome and/or has used or plans to use any of the following treatments for Cushing syndrome:
• • • Mifepristone, metyrapone, osilodrostat, ketoconazole, fluconazole, aminoglutethimide, etomidate, octreotide, lanreotide, pasireotide, longacting octreotide or pasireotide.
• • Is unable to take dexamethasone due to a history of hypersensitivity or severe reaction to dexamethasone.
• • Is a staff member working directly on the study or is a family member of someone working directly on the study, including any of the Sponsor's employees, the Investigator or the site staff.